Loading market dashboard
Psyence Biomedical Ltd.
PBMHealthcareNASDAQCA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused on the development and supply of nature-derived psychedelic compounds for clinical research and therapeutic applications, today announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in advancing psychedelic medicine research and policy initiatives.
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Pacific Bay Minerals Ltd. (TSXV: PBM) ("Pacific Bay" or the "Company") reports that the Company is adopting semi-annual financial reporting in place of quarterly reporting, effective for the three-month interim period ending (Q1 2026 period end date).
Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network
Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psychedelic therapies and manufacturing pharmaceutical-grade drug candidates, today provided an update on its strategic position in the global ibogaine market, as regulatory and clinical interest in the compound continues to expand.
Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain Through its investment in and collaboration with PsyLabs, the Company has established a GMP-compliant, pharmaceutical-grade supply chain
Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply Company highlights global leadership in GMP ibogaine manufacturing and commitment to ethically sourced supply
Calgary, Alberta – TheNewswire - April 14, 2026 – Aurwest Resources Corporation (“ Aurwest ” or the “ Company ”) ( CSE: AWR ) is pleased to announce that the Company has entered into a Definitive Option and Joint Venture Agreement (the “ Agreement ”) with Pacific Bay Minerals Ltd. (TSXV: PBM) whereby Aurwest has acquired an option to earn, subject to the satisfaction of conditions, an undivided interest of up to 50% in the Weaver Gold gold/silver property (the “ Transaction ”) in British Columbia. Transaction Summary
NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the expansion of its clinical site network in Australia from three to five sites supporting its ongoing clinical activities.
Psyence Biomedical (NASDAQ: PBM - Get Free Report) and XBiotech (NASDAQ: XBIT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Earnings and Valuation This table compares Psyence Biomedical
“The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig “The strongest companies are built on the right foundations long before their moment arrives,” says CEO Jody Aufrichtig
